Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin ...

The European Union (EU) is actively courting biotech for economic growth and has launched several initiatives to attract ...

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO ...

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to ...

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

In the 1980s, Lisa Conte was a biopharmaceutical venture capitalist. But she also was an aspiring entrepreneur, having a little business on the side called Wild Woods, which imported wood and ...

The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions. Those ...

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...

As anxiety disorders become more common and stress from the diverse impacts of the COVID-19 pandemic threaten the mental/emotional well-being of Americans everywhere, it is clear that the current ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.